Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07230834 · ClinicalTrials.gov registry record · Phase 1
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
A Phase 1 study of Geographic Atrophy (GA), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 4
- Study locations
NCT07230834: Recruiting Phase 1 study of Geographic Atrophy (GA), sponsored by Regeneron Pharmaceuticals.
NCT07230834 is a Phase 1 study of Geographic Atrophy (GA) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 54 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07230834, a Phase 1 study of Geographic Atrophy (GA), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to see. This is called geographic atrophy (GA). The aim of the study is to see how safe and tolerable the study drug is when used as an injection in the eye. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood and the fluid in the eye at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Primary Outcome
Part A
Conditions Studied
Interventions
- DRUG Pozelimab
Study Locations (4)
Texas
- Austin Retina Associates - Austin
- Retina Consultants Texas - The Woodlands
Colorado
- Colorado Retina Associates - Lakewood
Massachusetts
- Ophthalmic Consultants of Boston - East Weymouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2026-01-19 |
| Est. Completion | 2028-07-03 |
| Phase | Phase 1 |
What NCT07230834 shows while recruiting
NCT07230834 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Geographic Atrophy (GA) appearing as the primary indexed condition, and to 1 intervention - of which Pozelimab is the first listed.
NCT07230834 reports a single indexed study location in Texas, Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07230834 about?
NCT07230834 is a clinical study titled "Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants". This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to see. This is called geographic atrophy (GA). The aim of the study is to ...
What is the current status of trial NCT07230834?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2026-01-19. Estimated completion is 2028-07-03.
What conditions does trial NCT07230834 study?
This clinical trial studies the following conditions: Geographic Atrophy (GA).
What interventions are being tested in trial NCT07230834?
The interventions under investigation include: Pozelimab (DRUG).
Who is sponsoring clinical trial NCT07230834?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07230834 being conducted?
This trial has 4 study locations across Colorado, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy (GA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07230834's enrollment target sits among peer trials
54 932nd of 2000 higher than 1,053 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI